Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3) Beneish M-Score: -5.33 (As of Jul. 02, 2026)


BSP:ONCO3 Oncoclinicas Do Brasil Servicos Medicos SA BSP:ONCO3
43 GF Score
Price R$1.09
GF Value R$3.49
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Oncoclinicas Do Brasil Servicos Medicos Beneish M-Score?

Oncoclinicas Do Brasil Servicos Medicos BSP:ONCO3 -11.38% 43 Beneish M-Score is -5.33 as of Jul. 02, 2026. GuruFocus rates BSP:ONCO3 with a GF Score™ of 43/100 and a GF Value™ of R$3.49 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 630 Healthcare Providers & Services companies, Oncoclinicas Do Brasil Servicos Medicos ranks better than 96.19% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -5.33 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Oncoclinicas Do Brasil Servicos Medicos's Beneish M-Score or its related term are showing as below:

BSP:ONCO3' s Beneish M-Score Range Over the Past 10 Years
Min: -5.33   Med: -2.14   Max: -1.42
Current: -5.33

During the past 8 years, the highest Beneish M-Score of Oncoclinicas Do Brasil Servicos Medicos was -1.42. The lowest was -5.33. And the median was -2.14.


Oncoclinicas Do Brasil Servicos Medicos Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Oncoclinicas Do Brasil Servicos Medicos's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncoclinicas Do Brasil Servicos Medicos Beneish M-Score Chart

Oncoclinicas Do Brasil Servicos Medicos Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial -2.05 -1.46 -2.05 -2.61 -5.14

Oncoclinicas Do Brasil Servicos Medicos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.84 -2.78 -4.26 -5.14 -5.33

BSP:ONCO3 vs HCA, THC, DVA: Beneish M-Score Comparison

For the Medical Care Facilities subindustry, Oncoclinicas Do Brasil Servicos Medicos's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncoclinicas Do Brasil Servicos Medicos Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Oncoclinicas Do Brasil Servicos Medicos's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Oncoclinicas Do Brasil Servicos Medicos's Beneish M-Score falls into.


BSP:ONCO3
43GF Score
Oncoclinicas Do Brasil Servicos Medicos SA BSP:ONCO3
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncoclinicas Do Brasil Servicos Medicos Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Oncoclinicas Do Brasil Servicos Medicos for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8519+0.528 * 1.0923+0.404 * 0.9734+0.892 * 0.8635+0.115 * 0.897
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.059+4.679 * -0.534461-0.327 * 1.3406
=-5.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was R$1,462 Mil.
Revenue was 1160.771 + 1368.829 + 1412.993 + 1464.389 = R$5,407 Mil.
Gross Profit was 199.45 + 480.911 + 453.139 + 440.007 = R$1,574 Mil.
Total Current Assets was R$2,470 Mil.
Total Assets was R$6,700 Mil.
Property, Plant and Equipment(Net PPE) was R$1,077 Mil.
Depreciation, Depletion and Amortization(DDA) was R$296 Mil.
Selling, General, & Admin. Expense(SGA) was R$1,316 Mil.
Total Current Liabilities was R$5,350 Mil.
Long-Term Debt & Capital Lease Obligation was R$458 Mil.
Net Income was -364.204 + -1453.981 + -1882.321 + -140.992 = R$-3,841 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = R$0 Mil.
Cash Flow from Operations was -219.039 + 256.013 + 151.754 + -449.529 = R$-261 Mil.
Total Receivables was R$1,988 Mil.
Revenue was 1493.156 + 1566.04 + 1634.891 + 1567.63 = R$6,262 Mil.
Gross Profit was 412.244 + 503.078 + 548.092 + 526.968 = R$1,990 Mil.
Total Current Assets was R$4,203 Mil.
Total Assets was R$10,826 Mil.
Property, Plant and Equipment(Net PPE) was R$1,389 Mil.
Depreciation, Depletion and Amortization(DDA) was R$333 Mil.
Selling, General, & Admin. Expense(SGA) was R$1,439 Mil.
Total Current Liabilities was R$2,328 Mil.
Long-Term Debt & Capital Lease Obligation was R$4,673 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1462.265 / 5406.982) / (1987.845 / 6261.717)
=0.27044 / 0.31746
=0.8519

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1990.382 / 6261.717) / (1573.507 / 5406.982)
=0.317865 / 0.291014
=1.0923

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2469.726 + 1077.223) / 6699.638) / (1 - (4202.724 + 1389.379) / 10825.812)
=0.470576 / 0.483447
=0.9734

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=5406.982 / 6261.717
=0.8635

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(332.839 / (332.839 + 1389.379)) / (295.824 / (295.824 + 1077.223))
=0.193262 / 0.215451
=0.897

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1315.559 / 5406.982) / (1438.64 / 6261.717)
=0.243307 / 0.229752
=1.059

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((457.989 + 5350.118) / 6699.638) / ((4673.304 + 2327.665) / 10825.812)
=0.866928 / 0.646692
=1.3406

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-3841.498 - 0 - -260.801) / 6699.638
=-0.534461

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Oncoclinicas Do Brasil Servicos Medicos has a M-score of -5.33 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -5.33 mean?
Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3) has a Beneish M-Score of -5.33 as of Jul. 02, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Oncoclinicas Do Brasil Servicos Medicos and its competitors. According to the industry distribution chart, Oncoclinicas Do Brasil Servicos Medicos ranks #24 out of 630 companies in the Healthcare Providers & Services industry, placing it in the top 3.8%.
Is Oncoclinicas Do Brasil Servicos Medicos' Beneish M-Score too high?
Oncoclinicas Do Brasil Servicos Medicos' current Beneish M-Score is -5.33. Based on the distribution chart, Oncoclinicas Do Brasil Servicos Medicos ranks #24 out of 630 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Oncoclinicas Do Brasil Servicos Medicos has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncoclinicas Do Brasil Servicos Medicos' Beneish M-Score compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Oncoclinicas Do Brasil Servicos Medicos ranks #24 out of 630 companies for Beneish M-Score. This places Oncoclinicas Do Brasil Servicos Medicos in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Oncoclinicas Do Brasil Servicos Medicos and its competitors. Oncoclinicas Do Brasil Servicos Medicos's current Beneish M-Score is -5.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoclinicas Do Brasil Servicos Medicos stock overvalued right now?
Based on GuruFocus' analysis, Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3) is currently considered Possible Value Trap. The stock's GF Value™ is R$3.49, compared to a current price of R$1.09 — trading 68.8% below its estimated fair value. The current Beneish M-Score is -5.33. Oncoclinicas Do Brasil Servicos Medicos' overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3), the current Beneish M-Score is -5.33 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoclinicas Do Brasil Servicos Medicos stock appears to be undervalued. The current stock price of R$1.09 is trading 68.8% below its estimated GF Value™ of R$3.49. GuruFocus considers Oncoclinicas Do Brasil Servicos Medicos to be Possible Value Trap.

Key valuation signals for BSP:ONCO3:

  • Beneish M-Score: -5.33
  • GF Value™: R$3.49 vs. price of R$1.09 (68.8% below fair value)
  • GF Score™: 43/100 with 6 warning signs

No single metric tells the full story. See the BSP:ONCO3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncoclinicas Do Brasil Servicos Medicos Business Description

Address Avenida Presidente Juscelino Kubitschek, No. 510, 2nd Floor, Vila Nova Conceicao, Sao Paulo, SP, BRA, 04543-906
Oncoclinicas Do Brasil Servicos Medicos SA is engaged in the management and administration of oncological services. It has specialists in the areas of oncology, radiotherapy, hematology, and bone marrow transplantation, complementary care. The Group operates solely in the healthcare services segment, with an emphasis on oncology.
43GF Score

Get the complete analysis for BSP:ONCO3

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$1.09
Price
R$3.49
GF Value